ConexiantPCOS Renamed PMOS After Global Consensus

🎓 Expert Commentary / Peer Perspective
A global consensus initiative engaging 56 organizations and more than 14,000 patients and clinicians renamed PCOS to polyendocrine metabolic ovarian syndrome (PMOS). The change reframes the disorder around its multisystem endocrine and metabolic biology rather than ovarian cysts.

Clinical Considerations

• The condition affects an estimated 170 million women globally and remains underdiagnosed in up to 70% of affected patients.
• Diagnostic criteria remain unchanged: at least two of three features — ovulatory dysfunction, hyperandrogenism, or polycystic ovaries on ultrasound or elevated AMH.
• Insulin resistance and compensatory hyperinsulinemia were reported in 85% of affected patients, including 75% of lean patients.
• A 3-year transition period is planned, with incorporation into the 2028 international guideline update; ICD coding changes remain in progress.

Practice Applications

• Recognize that diagnostic criteria are unchanged; only nomenclature has shifted.
• Integrate new terminology gradually as patient education materials and EHR systems are updated.
• Monitor for associated cardiometabolic conditions including type 2 diabetes, dyslipidemia, hypertension, MASLD, and cardiovascular disease.
• Interpret existing ICD codes as still valid until formal WHO engagement concludes.